Miller Anestesia

390. Mystakidou K, Katsouda E, Parpa E, et al: Oral

transmucosal fentanyl citrate: Overview of pharma-

cological and clinical characteristics. Drug Deliv

13:269–276, 2006.

391. Dale O, Hjortkjaer R, Kharasch ED: Nasal adminis-

tration of opioids for pain management in adults.

Acta Anaesthesiol Scand 46:759–770, 2002.

392. Abboud TK, Zhu J, Gangolly J, et al: Transnasal

butorphanol: A new method for pain relief in post–

cesarean section pain. Acta Anaesthesiol Scand

35:14–18, 1991.

393. Striebel HW, Oelmann T, Spies C, et al: Patient-

controlled intranasal analgesia:A method for nonin-

vasive postoperative pain management. Anesth

Analg 83:548–551, 1996.

394. Karl HW, Keifer AT, Rosenberger JL, et al: Compa-

rison of the safety and efficacy of intranasal mida-

zolam or sufentanil for preinduction of anesthesia

in pediatric patients. Anesthesiology 76:209–215,

1992.

395. Zedie N, Amory DW, Wagner BK: O’Hara DA:

Comparison of intranasal midazolam and sufenta-

nil premedication in pediatric outpatients. Clin

Pharmacol Ther 59:341–348, 1996.

396. Worsley MH,MacLeodAD,Brodie MJ,et al: Inhaled

fentanyl as a method of analgesia. Anaesthesia

45:449–451, 1990.

397. Hung OR, Whynot SC, Varvel JR, et al: Pharmaco-

kinetics of inhaled liposome-encapsulated fentanyl.

Anesthesiology 83:277–284, 1995.

398. Coyne PJ, Viswanathan R, Smith TJ: Nebulized fen-

tanyl citrate improves patients’ perception of brea-

thing, respiratory rate, and oxygen saturation in

dyspnea. J Pain Symptom Manage 23:157–160, 2002.

399. Farr SJ, Otulana BA: Pulmonary delivery of opioids

as pain therapeutics. Adv Drug Deliv Rev 58:

1076–1088, 2006.

400. Babul N, Darke AC,Anslow JA, Krishnamurthy TN:

Pharmacokinetics of two novel rectal controlled-

release morphine formulations. J Pain Symptom

Manage 7:400–405, 1992.

401. Lundeberg S, Beck O, Olsson GL, Boreus LO: Rectal

administration of morphine in children. Pharmaco-

kinetic evaluation after a single-dose. Acta Anaes-

thesiol Scand 40:445–451, 1996.

402. Klepstad P, Kaasa S, Jystad A, et al: Immediate- or

sustained-release morphine for dose finding during

start of morphine to cancer patients: A randomized,

double-blind trial. Pain 101:193–198, 2003.

403. Ginsberg B, Sinatra RS, Adler LJ, et al: Conversion

to oral controlled-release oxycodone from intrave-

nous opioid analgesic in the postoperative setting.

Pain Med 4:31–38, 2003.

404. Curtis GB, Johnson GH, Clark P, et al: Relative

potency of controlled-release oxycodone and con-

trolled-release morphine in a postoperative pain

model. Eur J Clin Pharmacol 55:425–429, 1999.

405. Bruera E, Belzile M, Pituskin E, et al: Randomized,

double-blind, cross-over trial comparing safety and

efficacy of oral controlled-release oxycodone with

controlled-release morphine in patients with cancer

pain. J Clin Oncol 16:3222–3229, 1998.

406. Caraco Y, Tateishi T, Guengerich FP, Wood AJ:

Microsomal codeine

-demethylation: Cosegrega-

tion with cytochrome P4503A4 activity. Drug

Metab Dispos 24:761–764, 1996.

407. Parke TJ, Nandi PR, Bird KJ, Jewkes DA: Profound

hypotension following intravenous codeine

phosphate.Three case reports and some recommen-

dations. Anaesthesia 47:852–854, 1992.

408. Hill HF, Coda BA, Tanaka A, Schaffer R: Multiple-

dose evaluation of intravenous hydromorphone

pharmacokinetics in normal human subjects.

Anesth Analg 72:330–336, 1991.

409. Wallenstein SL, Houde RW, Portenoy R, et al: Clini-

cal analgesic assay of repeated and single doses of

heroin and hydromorphone. Pain 41:5–13, 1990.

410. Quigley C, Wiffen P: A systematic review of hydro-

morphone in acute and chronic pain. J Pain

Symptom Manage 25:169–178, 2003.

411. Rapp SE, Egan KJ, Ross BK, et al: A multidimensio-

nal comparison of morphine and hydromorphone

patient-controlled analgesia. Anesth Analg 82:

1043–1048, 1996.

412. Prommer E: Levorphanol: The forgotten opioid.

Support Care Cancer 15:259–264, 2007.

413. Bowdle TA, Even A, Shen DD, Swardstrom M:

Methadone for the induction of anesthesia: Plasma

histamine concentration, arterial blood pressure,

and heart rate. Anesth Analg 98:1692–1697, 2004.

414. Chamberlin KW, Cottle M, Neville R, Tan J: Oral

oxymorphone for pain management. Ann Pharma-

cother 41:1144–1152, 2007.

415. Gimbel J, Ahdieh H: The efficacy and safety of oral

immediate-release oxymorphone for postsurgical

pain. Anesth Analg 99:1472–1477, 2004.

416. Morlion B, Ebner E, Weber A, et al: Influence of

bolus size on efficacy of postoperative patient-con-

trolled analgesia with piritramide. Br J Anaesth

82:52–55, 1999.

417. Bouillon T, Kietzmann D, Port R, et al: Population

pharmacokinetics of piritramide in surgical patients.

Anesthesiology 90:7–15, 1999.

418. Halfpenny DM, Callado LF, Hopwood SE, et al:

Effects of tramadol stereoisomers on norepine-

phrine efflux and uptake in the rat locus coeruleus

measured by real time voltammetry. Br J Anaesth

83:909–915, 1999.

419. Bamigbade TA, Davidson C, Langford RM, Sta-

mford JA: Actions of tramadol, its enantiomers and

principal metabolite,

-desmethyltramadol, on

serotonin (5-HT) efflux and uptake in the rat dorsal

raphe nucleus. Br J Anaesth 79:352–356, 1997.

420. de Wolff MH, Leather HA, Wouters PF: Effects of

tramadol on minimum alveolar concentration

(MAC) of isoflurane in rats. Br J Anaesth 83:

780–783, 1999.

421. James MF, Heijke SA, Gordon PC: Intravenous tra-

madol versus epidural morphine for postthoraco-

tomy pain relief: A placebo-controlled double-blind

trial. Anesth Analg 83:87–91, 1996.

422. Vickers MD, O’Flaherty D, Szekely SM, et al: Trama-

dol: Pain relief by an opioid without depression of

respiration. Anaesthesia 47:291–296, 1992.

423. Wilder Smith CH, Bettiga A: The analgesic trama-

dol has minimal effect on gastrointestinal motor

function. Br J Clin Pharmacol 43:71–75, 1997.

424. Pang WW, Huang PY, Chang DP, Huang MH: The

peripheral analgesic effect of tramadol in redu-

cing propofol injection pain: A comparison with

lidocaine. Reg Anesth Pain Med 24:246–249,

1999.

425. Acalovschi I, Cristea T, Margarit S, Gavrus R: Tra-

madol added to lidocaine for intravenous regional

anesthesia. Anesth Analg 92:209–214, 2001.

426. Westman L, Valentin A, Eriksson E, Ekblom A:

Intrathecal administration of sameridine to patients

subjected to arthroscopic knee joint surgery. Acta

Anaesthesiol Scand 42:691–697, 1998.

427. Osterlund Modalen A, Arlander E, Eriksson LI,

Lindahl SG: The effects on hypercarbic ventilatory

response of sameridine compared to morphine and

placebo. Anesth Analg 92:529–534, 2001.

428. Osterlund A, Arlander E, Eriksson LI, Lindahl SG:

The effects on resting ventilation of intravenous

infusions of morphine or sameridine, a novel mole-

cule with both local anesthetic and opioid proper-

ties. Anesth Analg 88:160–165, 1999.

429. van Dorp EL, Romberg R, Sarton E, et al: Morphine-

6-glucuronide: Morphine’s successor for postopera-

tive pain relief? Anesth Analg 102:1789–1797,

2006.

430. Osborne R, Thompson P, Joel S, et al: The analgesic

activity of morphine-6-glucuronide. Br J Clin Phar-

macol 34:130–138, 1992.

431. Grace D, Fee JP: A comparison of intrathecal mor-

phine-6-glucuronide and intrathecal morphine

sulfate as analgesics for total hip replacement.

Anesth Analg 83:1055–1059, 1996.

432. Asai T, Mapleson WW, Power I: Effects of nalbu-

phine, pentazocine and U50488H on gastric emp-

tying and gastrointestinal transit in the rat. Br J

Anaesth 80:814–819, 1998.

433. Zacny JP, Lichtor JL, Klafta JM, et al: The effects of

transnasal butorphanol on mood and psychomotor

functioning in healthy volunteers. Anesth Analg

82:931–935, 1996.

434. Dahan A, Yassen A, Bijl H, et al: Comparison of the

respiratory effects of intravenous buprenorphine

and fentanyl in humans and rats. Br J Anaesth

94:825–834, 2005.

435. Lee SC, Wang JJ, Ho ST, Tao PL: Nalbuphine coad-

ministered with morphine prevents tolerance and

dependence. Anesth Analg 84:810–815, 1997.

436. Parker RK, Holtmann B, White PF: Patient-contro-

lled epidural analgesia: Interactions between nalbu-

phine and hydromorphone. Anesth Analg

84:757–763, 1997.

437. Weiss BM, Schmid ER, Gattiker RI: Comparison of

nalbuphine and fentanyl anesthesia for coronary

artery bypass surgery. Hemodynamics, hormonal

response, and postoperative respiratory depression.

Anesth Analg 73:521–529, 1991.

438. Charuluxananan S, Kyokong O, SomboonviboonW,

et al: Nalbuphine versus ondansetron for prevention

of intrathecal morphine–induced pruritus after

cesarean delivery. Anesth Analg 96:1789–1793,

2003.

439. Wang JJ, Ho ST, Lee SC, Liu YC: A comparison

among nalbuphine, meperidine, and placebo for

treating postanesthetic shivering. Anesth Analg

88:686–689, 1999.

440. Kranke P, Eberhart LH, Roewer N, Tramer MR:

Pharmacological treatment of postoperative shive-

ring: A quantitative systematic review of randomi-

zed controlled trials. Anesth Analg 94:453–460,

2002.

441. Ding Y, White PF: Comparative effects of ketorolac,

dezocine, and fentanyl as adjuvants during outpa-

tient anesthesia. Anesth Analg 75:566–571, 1992.

442. Cohen RI, Edwards WT, Kezer EA, et al: Serial

intravenous doses of dezocine, morphine, and

nalbuphine in the management of postoperative

pain for outpatients. Anesth Analg 77:533–539,

1993.

443. Freye E, Levy JV: Reflex activity caused by laryngos-

copy and intubation is obtunded differently by mep-

tazinol, nalbuphine and fentanyl. Eur J Anaesthesiol

24:53–58, 2007.

444. KendrickWD,Woods AM, Daly MY, et al: Naloxone

versus nalbuphine infusion for prophylaxis of epi-

dural morphine–induced pruritus. Anesth Analg

82:641–647, 1996.

445. Gan TJ, Ginsberg B, Glass PS, et al: Opioid-sparing

effects of a low-dose infusion of naloxone in patient-

administered morphine sulfate. Anesthesiology

87:1075–1081, 1997.

446. Fukuda K, Kato S, Shoda T, et al: Partial agonistic

activity of naloxone on the opioid receptors expres-

sed from complementary deoxyribonucleic acids in

Chinese hamster ovary cells. Anesth Analg 87:

450–455, 1998.

588

Farmacología y anestesia